Non-Executive Chairman
Brian Jamieson FCA

Brian Jamieson was Chief Executive of Minter Ellison Melbourne and a partner of the Minter Ellison Revenue Group from 2002-2005. He retired as Chief Executive of Minter Ellison Melbourne on 31 December 2005.  Prior to joining Minter Ellison, Mr Jamieson was Executive Officer at KPMG from 1998-2000, Managing Partner of KPMG Melbourne and Southern Regions from 1993-1998 and Chairman of KPMG Melbourne from 2001-2002.  He was also a KPMG Board Member in Australia , and a member of the USA Management Committee.  Mr Jamieson is a Non-Executive Director of Sigma Pharmaceuticals Limited, Oxiana Limited and HBOS Australia Pty Ltd.  He is also a Director and Treasurer of Care Australia and the Bionic Ear Institute, and a Director of Veski, The Sir Robert Menzies Foundation, the Australian Council - Major Performing Arts Board and the Tattersall's George Adams Foundation. Mr Jamieson has over 30 years of experience in providing advice and audit services to a diverse range of public and large private companies. He is a Fellow of the Institute of Chartered Accountants in Australia .

Non-Executive Deputy Chairman
Donal O'Dwyer, BE, MBA

Mr O'Dwyer has almost 20 years experience as a senior executive in the global cardiovascular and medical devices industries. From 2000 to 2003, he was worldwide president of Cordis Cardiology, the cardiology division of Johnson & Johnson's Cordis Corporation. Cordis is the world's largest manufacturer of innovative products for interventional medicine, minimally invasive computer-based imaging, and electrophysiology. In this role, Mr O'Dwyer led Cordis through the launch of the revolutionary Cypher drug eluting coronary stent technology, and saw the company take over number one market share of coronary stents worldwide. He directly supervised an increase in sales from $US500 million in 2000 to $US2 billion in 2003. Prior to joining Cordis in 1996, Mr O'Dwyer worked for 12 years with Baxter Healthcare, rising from plant manager in Ireland to president of the Cardiovascular Group, Europe , now Edwards Lifesciences. Mr O'Dwyer is a non-executive Director of Cochlear Limited and Sunshine Heart.

Director and Chief Scientific Adviser
Professor Silviu Itescu, MBBS (Hons), FRACP, FACP, FACR

Professor Itescu is the Founder of Mesoblast Limited and Angioblast Systems, Inc. Most recently Director of Transplantation Immunology at New York 's Columbia University Medical Center , Professor Itescu has established an outstanding international reputation in the fields of stem cell biology, autoimmune diseases, organ transplantation and heart failure. His experiences range from laboratory research to new drug development and clinical evaluation. Professor Itescu pioneered novel approaches to the use of adult stem cells for the treatment of heart disease and is leading international collaborative trials in this area. Professor Itescu was an advisor on cell therapy for cardiovascular diseases to both the United States President's Council on Bioethics and the US FDA Biological Response Modifiers Advisory Committee (BRMAC). He has consulted for many international pharmaceutical companies and has been an advisor to biotechnology and health care investor groups.

Non-Executive Director
Michael Spooner, BCom, ACA, MAICD

Mr Spooner has an extensive network of relationships with investment firms and business communities across the globe, having spent the majority of the past 25 years living and working internationally. He has an outstanding track record in the rapid international commercialisation of high growth companies including within the medical application and commercial technology sectors. Most recently, Mr Spooner was Managing Director & CEO of Ventracor Limited where he led the transformation of a small Australian listed life sciences company into the second highest performing stock on the S&P/ASX 200 index in 2003. He was a Principal Partner and Director of Consulting Services with PriceWaterhouse Coopers (Coopers & Lybrand) in Hong Kong for seven years. Mr Spooner advises a number of high growth corporations and is a non-executive Director of Peplin Limited.

Non-Executive Director
Byron McAllister, B.Sc, M.Ag

Mr McAllister has extensive expertise in product development, quality assurance, and obtaining FDA regulatory approvals within the healthcare industry. He has extensive expertise within the biologics, pharmaceutical, and medical device industries, and has prepared full documentation for approval by the U.S. FDA, UK MCA, and other world health regulatory authorities. Most recently, Mr McAllister has served as Vice President, Worldwide Quality Assurance, for the Ares-Serono Group based in Geneva and Boston , overseeing operations in over a dozen countries. Mr McAllister has held senior management positions in manufacturing and quality assurance with Abbott Laboratories' Ross Laboratories and Diagnostics Divisions, Amersham Corporation, and Coulter Electronics Corporation. He is a member of the PDA (Parenteral Drug Association), American Society For Quality (ASQ), and the Regulatory Affairs Professionals Society (RAPS).

Company Secretary
Kevin Hollingsworth, FCPA, FCMA

Mr. Hollingsworth is a certified public accountant, and a past chairman of both the National and Victorian Industry and Commerce Accountants Committees. Mr. Hollingsworth has most recently been non-executive director and company secretary for Alpha Technologies Corporation Ltd, a global company with operations in the US, Mexico and China, designing and manufacturing temperature sensors for disposable medical devices, as well as precision thermometry and instrumentation for the biotechnical and life science industry.